123 related articles for article (PubMed ID: 38558505)
1. TACE inhibition: a promising therapeutic intervention against AATF-mediated steatohepatitis to hepatocarcinogenesis.
Srinivas AN; Suresh D; Vishwanath PM; Satish S; Santhekadur PK; Koka S; Kumar DP
Mol Oncol; 2024 Apr; ():. PubMed ID: 38558505
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis antagonizing transcription factor-mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis-hepatocellular carcinoma.
Srinivas AN; Suresh D; Chidambaram SB; Santhekadur PK; Kumar DP
J Cell Physiol; 2024 Jan; 239(1):135-151. PubMed ID: 37942831
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.
Jiang JX; Chen X; Fukada H; Serizawa N; Devaraj S; Török NJ
Hepatology; 2013 Oct; 58(4):1339-48. PubMed ID: 23703665
[TBL] [Abstract][Full Text] [Related]
4. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.
Kumar DP; Santhekadur PK; Seneshaw M; Mirshahi F; Uram-Tuculescu C; Sanyal AJ
Hepatology; 2019 Apr; 69(4):1520-1534. PubMed ID: 30394550
[TBL] [Abstract][Full Text] [Related]
5. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.
de Meijer VE; Sverdlov DY; Popov Y; Le HD; Meisel JA; Nosé V; Schuppan D; Puder M
PLoS One; 2010 Jun; 5(6):e11256. PubMed ID: 20593020
[TBL] [Abstract][Full Text] [Related]
6. AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma.
Suresh D; Srinivas AN; Prashant A; Satish S; Vishwanath P; Nataraj SM; Koduru SV; Santhekadur PK; Kumar DP
Front Oncol; 2023; 13():1130380. PubMed ID: 37361585
[TBL] [Abstract][Full Text] [Related]
7. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.
Tsuchida T; Lee YA; Fujiwara N; Ybanez M; Allen B; Martins S; Fiel MI; Goossens N; Chou HI; Hoshida Y; Friedman SL
J Hepatol; 2018 Aug; 69(2):385-395. PubMed ID: 29572095
[TBL] [Abstract][Full Text] [Related]
8. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
9. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
10. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice.
Menghini R; Menini S; Amoruso R; Fiorentino L; Casagrande V; Marzano V; Tornei F; Bertucci P; Iacobini C; Serino M; Porzio O; Hribal ML; Folli F; Khokha R; Urbani A; Lauro R; Pugliese G; Federici M
Gastroenterology; 2009 Feb; 136(2):663-72.e4. PubMed ID: 19027012
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of tumor necrosis factor-α converting enzyme attenuates liver toxicity in a murine model of concanavalin A induced auto-immune hepatitis.
Sharma M; Mohapatra J; Malik U; Wagh A; Singh A; Patel HM; Pandey D; Kadam S; Shah GB; Chatterjee A; Jain MR
Int Immunopharmacol; 2013 Oct; 17(2):229-36. PubMed ID: 23816535
[TBL] [Abstract][Full Text] [Related]
13. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats.
Tang ZY; Loss G; Carmody I; Cohen AJ
Transplantation; 2006 Dec; 82(11):1518-23. PubMed ID: 17164725
[TBL] [Abstract][Full Text] [Related]
14. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice.
de Meijer VE; Le HD; Meisel JA; Sharma AK; Popov Y; Puder M
PLoS One; 2011; 6(9):e25587. PubMed ID: 21980496
[TBL] [Abstract][Full Text] [Related]
16. Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis.
Lyu J; Okada H; Sunagozaka H; Kawaguchi K; Shimakami T; Nio K; Murai K; Shirasaki T; Yoshida M; Arai K; Yamashita T; Tanaka T; Harada K; Takamura T; Kaneko S; Yamashita T; Honda M
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38619434
[TBL] [Abstract][Full Text] [Related]
17. Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization.
Jiang K; Lu S; Li D; Liu M; Jin H; Lei B; Wang S; Long K; He S; Zhong F
J Gastroenterol; 2023 Sep; 58(9):894-907. PubMed ID: 37227481
[TBL] [Abstract][Full Text] [Related]
18. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
19. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
20. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
